PT  - JOURNAL ARTICLE
AU  - Lee, Tae Yoon
AU  - Petkau, John
AU  - Johnson, Kate M.
AU  - Turvey, Stuart E.
AU  - Adibi, Amin
AU  - Subbarao, Padmaja
AU  - Sadatsafavi, Mohsen
TI  - Development and Validation of an Asthma Policy Model for Canada: Lifetime Exposures and Asthma outcomes Projection (LEAP)
AID  - 10.1101/2024.03.11.24304122
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.11.24304122
4099  - http://medrxiv.org/content/early/2024/03/13/2024.03.11.24304122.short
4100  - http://medrxiv.org/content/early/2024/03/13/2024.03.11.24304122.full
AB  - Purpose To develop Lifetime Exposures and Asthma outcomes Projection (LEAP), a reference policy model for evaluating health outcomes and costs of asthma interventions and policies for the Canadian population.Methods Following the best practice guidelines for development, we first created a conceptual map with a steering committee of clinician experts and economic modelers through a modified Delphi-process. Following the committee’s recommendations and given the multidimensionality of risk factors and the need for modeling realistic aspects (e.g., gradual market penetration) of adopting health technologies, we opted for an open-population microsimulation design. For the first version of the model, we concentrated on several key risk factors (age, sex, family history of asthma at birth, and exposure to antibiotics in the first year of life) from the concept map.The model consists of five intertwined modules: 1) demographic, 2) risk factors, 3) asthma occurrence, 4) asthma outcomes, and 5) payoffs. The demographic module, including birth, mortality, immigration, and emigration, was based on sex– and age-specific estimates and projections from Statistics Canada. The distributions of risk factors, including family history of asthma and exposure to antibiotics, were estimated from population-based administrative databases and a population-based longitudinal birth cohort. To estimate parameters in the asthma occurrence (prevalence, incidence, reassessment) and asthma outcomes (severity, symptom control, exacerbations) modules, we performed quantitative evidence synthesis. Costs and utility weights were obtained from the literature. We conducted multiple face and internal validation assessments.Results LEAP is capable of modeling asthma-related health outcomes at the individual and aggregate levels from 2001 onwards. Face validity was confirmed by checking the structure, equations, codes, and results. We calibrated and internally validated the age-sex stratified demographic projections to the estimates and projections from Statistics Canada, the age-sex stratified asthma prevalence to the administrative data, and the asthma control levels and exacerbation rates to the estimates from the literature.Conclusions LEAP is the first reference Canadian asthma policy model that emerged from identified needs for health policy planning for early interventions in asthma. As an open-source and open-access platform, LEAP can provide a unified framework under which different interventions and policies can be consistently compared to identify those with the highest value proposition.Funding This study was funded by a research grant from the Canadian Institutes of Health Research and Genome Canada (274CHI). The funders had no role in any aspect of this study and were not aware of the results.Ethics This study was approved by the institutional review board of the University of British Columbia, Vancouver (H22-00571).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a research grant from the Canadian Institutes of Health Research and Genome Canada (274CHI). The funders had no role in any aspect of this study and were not aware of the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of the University of British Columbia, Vancouver (H22-00571).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data open to the public are available online at https://github.com/tyhlee/LEAP.jl. The CHILD study cohort data is not open to the public. One can obtain access by following the procedures: https://childstudy.ca/for-researchers/data-access/.https://github.com/tyhlee/LEAP.jl